Cargando…
Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
Noradrenergic dysfunction contributes to cognitive impairment in Alzheimer's Disease (AD) and Parkinson's Disease (PD). Conventional therapeutic strategies seek to enhance cholinergic and dopaminergic neurotransmission in AD and PD, respectively, and few studies have examined noradrenergic...
Autores principales: | Peterson, Andrew C., Li, Chiang-shan R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5938376/ https://www.ncbi.nlm.nih.gov/pubmed/29765316 http://dx.doi.org/10.3389/fnagi.2018.00127 |
Ejemplares similares
-
Noradrenergic dysfunction in Alzheimer's disease
por: Gannon, Mary, et al.
Publicado: (2015) -
α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
por: Butkovich, Laura M., et al.
Publicado: (2018) -
New approaches for the quantification and targeting of noradrenergic dysfunction in Alzheimer's disease
por: David, Michael, et al.
Publicado: (2022) -
The Noradrenergic System in Parkinson’s Disease
por: Paredes-Rodriguez, Elena, et al.
Publicado: (2020) -
Noradrenergic therapies for apathy in Alzheimer’s disease?
por: Husain, Masud
Publicado: (2023)